We found that B and T/NK cells were suppressed in tumor tissues but upregulated following neoadjuvant treatment, particularly pB-IGHA2 and CD8_Tem-GZMK cells, which were more prevalent in patients who achieved CR/PR than in those with SD/PD, suggesting their antiSCLC activity. Here, IGHA2 is linked to neoplasm.